Cargando…

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ

The estrogen receptor-alpha (ERα) is used as a predictive marker for anti-estrogen therapy in breast cancer patients. In addition to aromatase inhibitors, ERα can be targeted at the receptor level using the receptor modulator tamoxifen or by the pure anti-estrogen fulvestrant. The role of the second...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Ameet K., Abrahamsson, Annelie, Dabrosin, Charlotta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302959/ https://www.ncbi.nlm.nih.gov/pubmed/27486755 http://dx.doi.org/10.18632/oncotarget.10871

Ejemplares similares

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo
por: Abrahamsson, Annelie, et al.
Publicado: (2015)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Equal Pro-inflammatory Profiles of CCLs, CXCLs, and Matrix Metalloproteinases in the Extracellular Microenvironment In Vivo in Human Dense Breast Tissue and Breast Cancer
por: Abrahamsson, Annelie, et al.
Publicado: (2018)

Tamoxifen and Flaxseed Alter Angiogenesis Regulators in Normal Human Breast Tissue In Vivo
por: Nilsson Åberg, Ulrika W., et al.
Publicado: (2011)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

Increased nutrient availability in dense breast tissue of postmenopausal women in vivo
por: Abrahamsson, Annelie, et al.
Publicado: (2017)

Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells
por: Qi, Wenwen, et al.
Publicado: (2016)

Breast density and estradiol are associated with distinct different expression patterns of metabolic proteins in normal human breast tissue in vivo
por: Ekstrand, Jimmy, et al.
Publicado: (2023)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination via Interleukin-8
por: Vazquez Rodriguez, Gabriela, et al.
Publicado: (2018)

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017)

Downregulation of tumor suppressive microRNAs in vivo in dense breast tissue of postmenopausal women
por: Abrahamsson, Annelie, et al.
Publicado: (2017)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Adipokines and Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo – Correlations and Attenuation by Dietary Flaxseed
por: Morad, Vivian, et al.
Publicado: (2016)

Lysine in Combination With Estradiol Promote Dissemination of Estrogen Receptor Positive Breast Cancer via Upregulation of U2AF1 and RPN2 Proteins
por: Vazquez Rodriguez, Gabriela, et al.
Publicado: (2020)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

CCN5/WISP-2 restores ER-∝ in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen
por: Sarkar, S, et al.
Publicado: (2017)

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

Breast Density and Estradiol Are Major Determinants for Soluble TNF-TNF-R Proteins in vivo in Human Breast Tissue
por: Ekstrand, Jimmy, et al.
Publicado: (2022)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer
por: Nagel, Anna, et al.
Publicado: (2022)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

Z-ligustilide restores tamoxifen sensitivity of ERα negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERα
por: Ma, Hui, et al.
Publicado: (2017)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
por: Hancock, G. R., et al.
Publicado: (2022)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
por: Lymperatou, Dionysia, et al.
Publicado: (2013)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Peterlongo, Paolo, et al.
Publicado: (2021)

PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients
por: Tonetti, Debra A., et al.
Publicado: (2012)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

Tamoxifen Inhibits ER-negative Breast Cancer Cell Invasion and Metastasis by Accelerating Twist1 Degradation
por: Ma, Gang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nkst03si10gsnqe29vjp0qgl2v